JP2003277293A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003277293A5 JP2003277293A5 JP2002013189A JP2002013189A JP2003277293A5 JP 2003277293 A5 JP2003277293 A5 JP 2003277293A5 JP 2002013189 A JP2002013189 A JP 2002013189A JP 2002013189 A JP2002013189 A JP 2002013189A JP 2003277293 A5 JP2003277293 A5 JP 2003277293A5
- Authority
- JP
- Japan
- Prior art keywords
- transplanted
- group
- heart
- ailim
- transplantation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002054 transplantation Methods 0.000 description 13
- 241000700159 Rattus Species 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 9
- 230000004083 survival effect Effects 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 5
- 206010052779 Transplant rejections Diseases 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 101001042104 Homo sapiens Inducible T-cell costimulator Proteins 0.000 description 4
- 102100021317 Inducible T-cell costimulator Human genes 0.000 description 4
- 230000008595 infiltration Effects 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 229940125721 immunosuppressive agent Drugs 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Images
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2002013189A JP4212278B2 (ja) | 2001-03-01 | 2002-01-22 | 移植片拒絶反応抑制剤 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2001056216 | 2001-03-01 | ||
| JP2001-56216 | 2001-03-01 | ||
| JP2001056209 | 2001-03-01 | ||
| JP2001-56209 | 2001-03-01 | ||
| JP2002008028 | 2002-01-16 | ||
| JP2002-8028 | 2002-01-16 | ||
| JP2002013189A JP4212278B2 (ja) | 2001-03-01 | 2002-01-22 | 移植片拒絶反応抑制剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2003277293A JP2003277293A (ja) | 2003-10-02 |
| JP2003277293A5 true JP2003277293A5 (https=) | 2004-12-24 |
| JP4212278B2 JP4212278B2 (ja) | 2009-01-21 |
Family
ID=27346134
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002013189A Expired - Fee Related JP4212278B2 (ja) | 2001-03-01 | 2002-01-22 | 移植片拒絶反応抑制剤 |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US7438905B2 (https=) |
| EP (2) | EP1769807B1 (https=) |
| JP (1) | JP4212278B2 (https=) |
| KR (1) | KR100609444B1 (https=) |
| CN (1) | CN1518458B (https=) |
| AT (2) | ATE352318T1 (https=) |
| AU (1) | AU2002228435B2 (https=) |
| BR (1) | BR0207787A (https=) |
| CA (1) | CA2439858C (https=) |
| CY (1) | CY1110143T1 (https=) |
| CZ (1) | CZ20032406A3 (https=) |
| DE (2) | DE60235928D1 (https=) |
| DK (1) | DK1769807T3 (https=) |
| ES (1) | ES2344219T3 (https=) |
| HU (2) | HU228045B1 (https=) |
| IL (2) | IL156845A0 (https=) |
| MX (1) | MXPA03006736A (https=) |
| NO (2) | NO331690B1 (https=) |
| NZ (1) | NZ527076A (https=) |
| PT (1) | PT1769807E (https=) |
| RU (1) | RU2263512C2 (https=) |
| SI (1) | SI1769807T1 (https=) |
| SK (1) | SK288048B6 (https=) |
| WO (1) | WO2002070010A1 (https=) |
Families Citing this family (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7112655B1 (en) | 1997-02-27 | 2006-09-26 | Japan Tobacco, Inc. | JTT-1 protein and methods of inhibiting lymphocyte activation |
| JP3521382B2 (ja) | 1997-02-27 | 2004-04-19 | 日本たばこ産業株式会社 | 細胞間接着及びシグナル伝達を媒介する細胞表面分子 |
| DE19821060A1 (de) * | 1997-09-23 | 1999-04-15 | Bundesrepublik Deutschland Let | Ko-stimulierendes Polypeptid von T-Zellen, monoklonale Antikörper sowie die Herstellung und deren Verwendung |
| JP4210454B2 (ja) | 2001-03-27 | 2009-01-21 | 日本たばこ産業株式会社 | 炎症性腸疾患治療剤 |
| JP3871503B2 (ja) | 1999-08-30 | 2007-01-24 | 日本たばこ産業株式会社 | 免疫性疾患治療剤 |
| CN1411373A (zh) * | 1999-12-16 | 2003-04-16 | 特瓦制药工业有限公司 | 制备来氟米特的新方法和新晶形的来氟米特 |
| JP3597140B2 (ja) | 2000-05-18 | 2004-12-02 | 日本たばこ産業株式会社 | 副刺激伝達分子ａｉｌｉｍに対するヒトモノクローナル抗体及びその医薬用途 |
| JP4212278B2 (ja) | 2001-03-01 | 2009-01-21 | 日本たばこ産業株式会社 | 移植片拒絶反応抑制剤 |
| RU2291675C2 (ru) * | 2004-07-09 | 2007-01-20 | Институт теоретической и экспериментальной биофизики РАН | Способ обработки трансплантатов для сердечно-сосудистой хирургии |
| GB0504544D0 (en) * | 2005-03-04 | 2005-04-13 | Novartis Ag | Organic compounds |
| JP2006321765A (ja) * | 2005-05-20 | 2006-11-30 | Mikiko Ueda | 肝移植における拒絶反応の予防又は治療薬、或いは拒絶反応とは断定できない肝機能異常の治療薬 |
| AU2008247382B2 (en) * | 2007-05-07 | 2014-06-05 | Medimmune, Llc | Anti-ICOS antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
| US9931386B2 (en) * | 2008-06-16 | 2018-04-03 | Atsuo Ochi | Recombinant multiple domain fusion protein mitogens and use thereof for inducing enhancement or repression of antigen-specific immunity |
| EP2455396A4 (en) * | 2009-07-16 | 2013-05-01 | Otsuka Chemical Co Ltd | EXTRACELLULAR AILIM DOMAIN PLACED WITH SUGAR CHAINS AND METHOD OF MANUFACTURING THE SAME |
| US9420770B2 (en) | 2009-12-01 | 2016-08-23 | Indiana University Research & Technology Corporation | Methods of modulating thrombocytopenia and modified transgenic pigs |
| WO2011130322A1 (en) * | 2010-04-12 | 2011-10-20 | University Of Miami | Macroporous bioengineered scaffolds for cell transplantation |
| EP3147297B1 (en) * | 2011-03-31 | 2018-12-12 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies directed against icos and uses thereof |
| US20150139994A1 (en) * | 2013-11-12 | 2015-05-21 | The Regents Of The University Of California | Compositions and methods for preventing allogeneic immune rejection |
| EP4162947A1 (en) * | 2013-11-22 | 2023-04-12 | Takeda Pharmaceutical Company Limited | Methods of treating antibody-mediated rejection in organ transplant patients with c1-esterase inhibitor |
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| US10941446B2 (en) | 2014-03-12 | 2021-03-09 | Icahn School Of Medicine At Mount Sinai | Method for identifying kidney allograft recipients at risk for chronic injury |
| CN113444783B (zh) | 2014-06-26 | 2024-04-09 | 西奈山伊坎医学院 | 通过分析预示性基因集诊断亚临床和临床的急性排异的方法 |
| ES2897004T3 (es) | 2014-06-26 | 2022-02-28 | Icahn School Med Mount Sinai | Métodos para diagnosticar el riesgo de fibrosis y rechazo de aloinjerto renal |
| MA41414A (fr) | 2015-01-28 | 2017-12-05 | Centre Nat Rech Scient | Protéines de liaison agonistes d' icos |
| CN107849084B (zh) | 2015-12-03 | 2021-09-14 | 葛兰素史密斯克莱知识产权发展有限公司 | 作为sting调节剂的环状嘌呤二核苷酸 |
| WO2017098421A1 (en) | 2015-12-08 | 2017-06-15 | Glaxosmithkline Intellectual Property Development Limited | Benzothiadiazine compounds |
| WO2017153952A1 (en) | 2016-03-10 | 2017-09-14 | Glaxosmithkline Intellectual Property Development Limited | 5-sulfamoyl-2-hydroxybenzamide derivatives |
| JP2019510802A (ja) | 2016-04-07 | 2019-04-18 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | タンパク質調節物質として有用な複素環アミド |
| PT3440076T (pt) | 2016-04-07 | 2022-07-29 | Glaxosmithkline Ip Dev Ltd | Amidas heterocíclicas úteis como modeladores de proteína |
| KR20190003699A (ko) | 2016-05-05 | 2019-01-09 | 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 | 제스트 인핸서 상동체 2 억제제 |
| WO2018029474A2 (en) | 2016-08-09 | 2018-02-15 | Kymab Limited | Anti-icos antibodies |
| US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
| RU2769282C2 (ru) | 2016-06-20 | 2022-03-30 | Кимаб Лимитед | Анти-PD-L1 и IL-2 цитокины |
| US20190241573A1 (en) | 2016-07-20 | 2019-08-08 | Glaxosmithkline Intellectual Property Development Limited | Isoquinoline derivatives as perk inhibitors |
| US11858996B2 (en) | 2016-08-09 | 2024-01-02 | Kymab Limited | Anti-ICOS antibodies |
| EP3534947A1 (en) | 2016-11-03 | 2019-09-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
| US20200062735A1 (en) | 2017-02-27 | 2020-02-27 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides as kinase inhibitors |
| BR112019025913A2 (pt) | 2017-06-09 | 2020-06-30 | Glaxosmithkline Intellectual Property Development Limited | métodos para tratar câncer em um paciente em necesssidade do mesmo e para produzir um anticorpo, anticorpo anti-icos ou fragmento de ligação ao antígeno do mesmo e um anticorpo anti-ox40 ou fragmento de ligação ao antígeno do mesmo, uso de um anticorpo anti-icos ou porção de ligação ao antígeno do mesmo e um anticorpo anti-ox40 ou porção de ligação ao antígeno do mesmo na fabricação de um medicamento, polinucleotídeo que codifica um anticorpo, vetor, e, célula hospedeira. |
| JP2020522555A (ja) | 2017-06-09 | 2020-07-30 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | 組み合わせ療法 |
| JP2020522556A (ja) | 2017-06-09 | 2020-07-30 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | 癌を治療するためのｉｃｏｓアゴニストおよびｏｘ４０アゴニストでの組み合わせ療法 |
| GB201709808D0 (en) | 2017-06-20 | 2017-08-02 | Kymab Ltd | Antibodies |
| WO2019021208A1 (en) | 2017-07-27 | 2019-01-31 | Glaxosmithkline Intellectual Property Development Limited | USEFUL INDAZOLE DERIVATIVES AS PERK INHIBITORS |
| WO2019053617A1 (en) | 2017-09-12 | 2019-03-21 | Glaxosmithkline Intellectual Property Development Limited | CHEMICAL COMPOUNDS |
| EP3692066A2 (en) | 2017-09-14 | 2020-08-12 | GlaxoSmithKline Intellectual Property Development Limited | Combination treatment for cancer |
| CA3077337A1 (en) | 2017-10-05 | 2019-04-11 | Glaxosmithkline Intellectual Property Development Limited | Modulators of stimulator of interferon genes (sting) |
| AU2018344902B2 (en) | 2017-10-05 | 2021-06-03 | Glaxosmithkline Intellectual Property Development Limited | Modulators of stimulator of interferon genes (STING) useful in treating HIV |
| EP3728314A1 (en) | 2017-12-19 | 2020-10-28 | Kymab Limited | Bispecific antibody for icos and pd-l1 |
| GB201721338D0 (en) | 2017-12-19 | 2018-01-31 | Kymab Ltd | Anti-icos Antibodies |
| RU2688172C1 (ru) * | 2018-04-05 | 2019-05-20 | Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" (ГБУЗ МО МОНИКИ им. М.Ф. Владимирского) | Способ профилактики отторжения трансплантата трупной почки |
| CA3095198A1 (en) | 2018-04-16 | 2019-10-24 | Icahn School Of Medicine At Mount Sinai | Method and kits for prediction of acute rejection and renal allograft loss using pre-transplant transcriptomic signatures in recipient blood |
| GB201807924D0 (en) | 2018-05-16 | 2018-06-27 | Ctxt Pty Ltd | Compounds |
| JP2021525271A (ja) | 2018-05-31 | 2021-09-24 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | Ｉｃｏｓ結合タンパク質及びアルギニンメチルトランスフェラーゼ阻害剤を用いた複合療法 |
| US20210267973A1 (en) | 2018-05-31 | 2021-09-02 | Glaxosmithkline Intellectual Property Development Limited | Combination of a type ii protein arginine methyltransferase inhibitor and an icos binding protein to treat cancer |
| WO2020031087A1 (en) | 2018-08-06 | 2020-02-13 | Glaxosmithkline Intellectual Property Development Limited | Combination therapy |
| BR112021007517A2 (pt) | 2018-10-22 | 2021-10-26 | Glaxosmithkline Intellectual Property Development Limited | Dosagem |
| US20200368369A1 (en) * | 2019-05-22 | 2020-11-26 | Wyvern Pharmaceuticals Inc. | Composition for endogenous production of checkpoint protein precursors |
| GB201910305D0 (en) | 2019-07-18 | 2019-09-04 | Ctxt Pty Ltd | Compounds |
| GB201910304D0 (en) | 2019-07-18 | 2019-09-04 | Ctxt Pty Ltd | Compounds |
| WO2021018941A1 (en) | 2019-07-31 | 2021-02-04 | Glaxosmithkline Intellectual Property Development Limited | Methods of treating cancer |
| WO2021043961A1 (en) | 2019-09-06 | 2021-03-11 | Glaxosmithkline Intellectual Property Development Limited | Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and chemotherapy |
| WO2021046289A1 (en) | 2019-09-06 | 2021-03-11 | Glaxosmithkline Intellectual Property Development Limited | Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and ipilimumab |
| WO2021058711A2 (en) | 2019-09-27 | 2021-04-01 | Glaxosmithkline Intellectual Property Development Limited | Antigen binding proteins |
| EP4077318B1 (en) | 2019-12-18 | 2025-10-15 | Ctxt Pty Ltd | Benzimidazole dimers as modulators of sting |
| CN113294813B (zh) * | 2020-02-24 | 2022-09-02 | 宁波方太厨具有限公司 | 一种电磁灶 |
| AU2021256652A1 (en) | 2020-04-14 | 2022-11-03 | Glaxosmithkline Intellectual Property Development Limited | Combination treatment for cancer involving anti-ICOS and anti-PD1 antibodies, optionally further involving anti-tim3 antibodies |
| JP2023521227A (ja) | 2020-04-14 | 2023-05-23 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド | 癌の併用療法 |
| CA3175490A1 (en) | 2020-04-14 | 2021-10-21 | Glaxosmithkline Intellectual Property Limited | Combination treatment for cancer based upon an icos antibody and a pd-l1 antibody tgf-beta-receptor fusion protein |
| GB202007099D0 (en) | 2020-05-14 | 2020-07-01 | Kymab Ltd | Tumour biomarkers for immunotherapy |
| CA3212345A1 (en) | 2021-03-02 | 2022-09-09 | Glaxosmithkline Intellectual Property Development Limited | Substituted pyridines as dnmt1 inhibitors |
| JP2024511831A (ja) | 2021-03-31 | 2024-03-15 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド | 抗原結合タンパク質およびそれらの組み合わせ |
| TW202313682A (zh) | 2021-05-18 | 2023-04-01 | 英商凱麥博有限公司 | 抗icos抗體之用途 |
| GB202107994D0 (en) | 2021-06-04 | 2021-07-21 | Kymab Ltd | Treatment of cancer |
| WO2023222854A1 (en) | 2022-05-18 | 2023-11-23 | Kymab Limited | Uses of anti-icos antibodies |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5506126A (en) * | 1988-02-25 | 1996-04-09 | The General Hospital Corporation | Rapid immunoselection cloning method |
| US6075181A (en) * | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6641809B1 (en) * | 1990-03-26 | 2003-11-04 | Bristol-Myers Squibb Company | Method of regulating cellular processes mediated by B7 and CD28 |
| IL102176A (en) * | 1991-06-11 | 2001-09-13 | Blood Res Center | Recombinant nucleic acid molecule capable of encoding intercellular adhesion molecule 3, functional derivatives of icam-3 and pharmaceutical compositions containing icam-3 or functional derivatives thereof |
| US5770197A (en) * | 1991-06-27 | 1998-06-23 | Bristol-Myers Squibb Company | Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules |
| JP3162438B2 (ja) | 1991-09-12 | 2001-04-25 | 住友製薬株式会社 | 高感度特異的抗体測定法 |
| US5484892A (en) * | 1993-05-21 | 1996-01-16 | Dana-Farber Cancer Institute, Inc. | Monoclonal antibodies that block ligand binding to the CD22 receptor in mature B cells |
| US6719972B1 (en) * | 1994-06-03 | 2004-04-13 | Repligen Corporation | Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA4- specific antibodies |
| US5747461A (en) * | 1994-07-26 | 1998-05-05 | Markov; Angel K. | Synergistic administration of cyclosporine and fructose diphosphate |
| CA2242414C (en) | 1996-01-23 | 2012-01-03 | Genentech, Inc. | Anti-cd18 antibodies for use against stroke |
| US5914112A (en) * | 1996-01-23 | 1999-06-22 | Genentech, Inc. | Anti-CD18 antibodies in stroke |
| NZ334714A (en) | 1996-09-18 | 2000-08-25 | Zetesis Spa | Liver proteins as agents against autoimmune diseases |
| DE69739725D1 (de) * | 1996-11-08 | 2010-02-11 | Biogen Idec Inc | Identifikation von bindungs- interaktionen zwischen gewissen antikorpern und den humanen costimulatorischen antigenen b7.1 (cd80) und b7.2 (cd28) |
| AU4145597A (en) | 1997-02-20 | 1998-09-09 | Cedars-Sinai Medical Center | Ulcerative colitis panca secretory vesicle antigen and methods of using sa me |
| FI107538B (fi) * | 1997-02-26 | 2001-08-31 | Raisio Benecol Oy | Menetelmä stanoliesterien valmistamiseksi |
| US7112655B1 (en) * | 1997-02-27 | 2006-09-26 | Japan Tobacco, Inc. | JTT-1 protein and methods of inhibiting lymphocyte activation |
| JP3521382B2 (ja) * | 1997-02-27 | 2004-04-19 | 日本たばこ産業株式会社 | 細胞間接着及びシグナル伝達を媒介する細胞表面分子 |
| WO2001018022A1 (en) | 1999-09-03 | 2001-03-15 | Human Genome Sciences, Inc. | 52 human secreted proteins |
| KR100816621B1 (ko) | 1997-04-07 | 2008-03-24 | 제넨테크, 인크. | 항-ｖｅｇｆ 항체 |
| DE19821060A1 (de) * | 1997-09-23 | 1999-04-15 | Bundesrepublik Deutschland Let | Ko-stimulierendes Polypeptid von T-Zellen, monoklonale Antikörper sowie die Herstellung und deren Verwendung |
| CA2305350C (en) | 1997-09-23 | 2015-04-07 | Bundesrepublik Deutschland Letztvertreten Durch Den Direktor Des Robert-Koch-Instituts | Costimulating polypeptide of t cells, monoclonal antibodies, and the preparation and use thereof |
| JPH11228442A (ja) * | 1998-02-09 | 1999-08-24 | Cypros Pharmaceut Corp | 臓器移植後のシクロスポリン投与量を低減するためのフルクトース二リン酸の使用 |
| JP2000154151A (ja) * | 1998-09-14 | 2000-06-06 | Kyo Jo | 免疫抑制剤 |
| AU767241B2 (en) * | 1998-09-14 | 2003-11-06 | Qiang Xu | Immunosuppressive agents |
| EP1119253A4 (en) | 1998-10-07 | 2005-12-21 | Millennium Pharm Inc | NEW SPECIFIC MOLECULES OF Th2 AND USES THEREOF |
| AU773954B2 (en) * | 1999-02-03 | 2004-06-10 | Amgen, Inc. | Novel Polypeptides involved in immune response |
| BR0010711A (pt) | 1999-05-06 | 2002-02-13 | Genetics Inst | Uso de moléculas co-estimulatórias solúveis para intensificar respostas imunes |
| AU6615500A (en) | 1999-07-28 | 2001-02-19 | Genetics Institute Inc. | Preventing immune-mediated abortion by inhibiting costimulation |
| WO2001012658A2 (en) | 1999-08-11 | 2001-02-22 | Isis Innovations Limited | Human icos ligand and application thereof |
| JP4210454B2 (ja) | 2001-03-27 | 2009-01-21 | 日本たばこ産業株式会社 | 炎症性腸疾患治療剤 |
| JP3871503B2 (ja) * | 1999-08-30 | 2007-01-24 | 日本たばこ産業株式会社 | 免疫性疾患治療剤 |
| DK1218504T3 (da) | 1999-09-21 | 2007-11-12 | Genetics Inst Llc | GL50 molekyler og anvendelser deraf |
| EP1224201A4 (en) | 1999-10-29 | 2005-03-02 | Human Genome Sciences Inc | 32 HUMAN SECRETED PROTEINS |
| WO2001064704A1 (en) | 2000-03-02 | 2001-09-07 | Mayo Foundation For Medical Education And Research | hB7-H2, A NOVEL CO-STIMULATORY MOLECULE |
| JP3597140B2 (ja) * | 2000-05-18 | 2004-12-02 | 日本たばこ産業株式会社 | 副刺激伝達分子ａｉｌｉｍに対するヒトモノクローナル抗体及びその医薬用途 |
| JP4236925B2 (ja) | 2000-11-28 | 2009-03-11 | アムジエン・インコーポレーテツド | 免疫応答に関与する新規ポリペプチド |
| JP4212278B2 (ja) | 2001-03-01 | 2009-01-21 | 日本たばこ産業株式会社 | 移植片拒絶反応抑制剤 |
-
2002
- 2002-01-22 JP JP2002013189A patent/JP4212278B2/ja not_active Expired - Fee Related
- 2002-02-05 RU RU2003129166/15A patent/RU2263512C2/ru not_active IP Right Cessation
- 2002-02-05 CN CN028058054A patent/CN1518458B/zh not_active Expired - Fee Related
- 2002-02-05 EP EP06024523A patent/EP1769807B1/en not_active Expired - Lifetime
- 2002-02-05 HU HU0303332A patent/HU228045B1/hu not_active IP Right Cessation
- 2002-02-05 DE DE60235928T patent/DE60235928D1/de not_active Expired - Lifetime
- 2002-02-05 AT AT02710508T patent/ATE352318T1/de not_active IP Right Cessation
- 2002-02-05 ES ES06024523T patent/ES2344219T3/es not_active Expired - Lifetime
- 2002-02-05 KR KR1020037011255A patent/KR100609444B1/ko not_active Expired - Fee Related
- 2002-02-05 PT PT06024523T patent/PT1769807E/pt unknown
- 2002-02-05 MX MXPA03006736A patent/MXPA03006736A/es active IP Right Grant
- 2002-02-05 CA CA002439858A patent/CA2439858C/en not_active Expired - Fee Related
- 2002-02-05 HU HU1100018A patent/HU228108B1/hu not_active IP Right Cessation
- 2002-02-05 DE DE60217839T patent/DE60217839T2/de not_active Expired - Lifetime
- 2002-02-05 WO PCT/JP2002/000930 patent/WO2002070010A1/ja not_active Ceased
- 2002-02-05 NZ NZ527076A patent/NZ527076A/xx not_active IP Right Cessation
- 2002-02-05 AT AT06024523T patent/ATE463256T1/de active
- 2002-02-05 IL IL15684502A patent/IL156845A0/xx active IP Right Grant
- 2002-02-05 DK DK06024523.0T patent/DK1769807T3/da active
- 2002-02-05 SK SK1214-2003A patent/SK288048B6/sk not_active IP Right Cessation
- 2002-02-05 BR BR0207787-6A patent/BR0207787A/pt not_active IP Right Cessation
- 2002-02-05 SI SI200230901T patent/SI1769807T1/sl unknown
- 2002-02-05 EP EP02710508A patent/EP1374901B9/en not_active Expired - Lifetime
- 2002-02-05 AU AU2002228435A patent/AU2002228435B2/en not_active Ceased
- 2002-02-05 CZ CZ20032406A patent/CZ20032406A3/cs unknown
-
2003
- 2003-07-09 IL IL156845A patent/IL156845A/en not_active IP Right Cessation
- 2003-08-29 NO NO20033839A patent/NO331690B1/no not_active IP Right Cessation
-
2004
- 2004-03-04 US US10/793,171 patent/US7438905B2/en not_active Expired - Fee Related
-
2008
- 2008-09-12 US US12/209,643 patent/US20090047292A1/en not_active Abandoned
-
2010
- 2010-06-04 CY CY20101100496T patent/CY1110143T1/el unknown
-
2011
- 2011-02-08 NO NO20110218A patent/NO20110218L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003277293A5 (https=) | ||
| JP2003511398A5 (https=) | ||
| Starzl | The saga of liver replacement, with particular reference to the reciprocal influence of liver and kidney transplantation (1955–1967) | |
| CA2387542A1 (en) | Supernatant from mesenchymal stem cells for prevention and treatment of immune responses in transplantation | |
| JP2004506598A5 (https=) | ||
| WO1995028957A3 (en) | Methods for inducing t cell tolerance to a tissue or organ graft | |
| Wu et al. | Improvement of Liver Transplantation Outcome by Heme Oxygenase‐1‐Transduced Bone Marrow Mesenchymal Stem Cells in Rats | |
| DE69331778D1 (de) | Induzierte toleranz gegen transplantate | |
| Bourget et al. | Tolerance to Musculoskeletal Allografts With Transient Lymphocyte Chimerism in Miniature Swine1 | |
| WO2002017935A3 (en) | A method of transplantation using chemotherapy-treated allogeneic cells that enhance immune responses without graft versus host disease | |
| Ajiki et al. | Generation of donor hematolymphoid cells after rat-limb composite grafting | |
| WO2004052305A3 (en) | Lactoferrin as an agent in the prevention of organ transplant rejection and graft-versus-host-disease | |
| MoTTRAM et al. | T suppressor cells induced by transfusions and cyclosporine: studies in the murine cardiac allograft model | |
| Hashimoto et al. | Short-course immunosuppression using FK506 for rat tracheal allografts | |
| PT652943E (pt) | Células hematopoiéticas facilitadoras e seus usos | |
| Tsuchida et al. | Vascularized bone marrow allotransplantation in rats prolongs a simultaneous skin allograft | |
| Svehag et al. | Synergism between alloantibodies or F (ab') 2 and prednisone in the survival of murine split heart allografts | |
| SHELBY et al. | Transmission of cytomegalovirus infection in mice by skin graft | |
| Löffeler et al. | Different kinetics of donor cell populations after isolated liver and combined liver/small bowel transplantation | |
| KASAHARA et al. | Antigen dependence of cyclosporin A-induced allograft acceptance | |
| Kemp et al. | Hope for successful xenografting by immunosuppression with monoclonal antibody against CD4, total lymphoid irradiation and cyclosporine: six months' survival of hamster heart transplanted into rat | |
| Zhao et al. | Vascularized whole thymus transplantation in Rowett nude rats: Effect of thymus allograft volume on tolerance induction | |
| Barone et al. | Vascularized Composite Allograft Tolerance Across A Full MHC Mismatch Is Possible With Transient High Dose Tacrolimus | |
| Brenner | Progress and Breakthrough in Preclinical and Clinical Cardiac Xenotransplantation | |
| Gratwohl et al. | Cyclosporine resistant effector cells in rabbit skin allografts |